As the premier source of global pharmaceutical market intelligence, we create essential value for our clients and deliver strong financial results for our shareowners. IMS (NYSE: RX) is committed to building shareowner value -- a commitment based on our reputation for leadership and innovation, our global coverage, our customer base, our unmatched data assets and our expertise. IMS's financial model is characterized by strong operating leverage, high free cash flow and a predictable revenue stream that provides our business with financial flexibility, balance sheet strength and a high return on investment for our shareholders.  |
New Study Highlights Rising Number of Type 2 Diabetes Patients in U.S., Increasing Complexity of Treatments| Health Services Research Network Academics Use IMS's Extensive Information Assets to Assess Trends in Managing a Disease Affecting MillionsNORWALK, Conn., Nov 18, 2008 (BUSINESS WIRE) -- An increasing number of type 2 diabetes patients in the U.S. are being
treated by a progressively complex mix of therapies, according to a
study featured in Archives of Internal Medicine, a JAMA/Archives
journal. The report is the first to be published by members of the
Health Ser... |
| IMS to Present at Credit Suisse Conference on November 12 at 10:30 a.m. MST| NORWALK, Conn.--(BUSINESS WIRE)--Nov. 5, 2008--IMS Health (NYSE:
RX), the world's leading provider of market intelligence to the
pharmaceutical and healthcare industries, today announced that Leslye
G. Katz, senior vice president and chief financial officer, will speak
to investors and analysts attending the 2008 Annual Credit Suisse
Health Care Conference, to be held at the Arizona Biltmore Resort &
Spa in Phoenix, AZ on November 11-14, 2008.
To listen to a live audio Webcast of ... |
| IMS Health Forecasts 4.5 - 5.5 Percent Growth for Global Pharmaceutical Market in 2009, Exceeding $820 Billion|
Key Dynamics Shaping Market:
-- Robust, double-digit growth in 'pharmerging' markets
-- Increased focus on specialty-driven therapies
-- Leveling of U.S. growth at 1 - 2 percent
-- Worldwide economic volatility
NORWALK, Conn.--(BUSINESS WIRE)--Oct. 29, 2008--The global
pharmaceutical market is expected to grow 4.5 - 5.5 percent next year,
a pace similar to 2008, according to the IMS Global Pharmaceutical and
Therapy Forecast(TM) rel... |
| IMS Health Delivers Double-Digit Net Income and EPS Growth In Third Quarter; Revenue Up 6 Percent| NORWALK, Conn.--(BUSINESS WIRE)--
IMS Health (NYSE: RX), the world's leading provider of market
intelligence to the pharmaceutical and healthcare industries, today
announced third-quarter 2008 revenue of $573.7 million, up 6 percent
or 3 percent year over year on a constant-dollar basis. Net income and
EPS grew 33 percent and 41 percent, respectively, in the quarter.
After adjusting for certain items, net income rose 11 percent and EPS
was up 19 percent (See below and Note c to the fi... |
|
|
| | There are currently no events scheduled. |
|
|
|
